14-3-3 Protein: A Potential Drug Target and Biomarker (P19795)

Target Name: 14-3-3 Protein

NCBI ID: P19795

14-3-3 Protein

Other Name(s): 14-3-3

14-3-3 Protein: A Potential Drug Target and Biomarker

Introduction

Protein 14-3-3, also known as GLUT14, is a key regulator of cell signaling pathways, including the TGF-β pathway. This pathway plays a crucial role in the development, maintenance, and regression of tissues, including muscles, bones, and skin. Malfunctioning GLUT14 has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, targeting GLUT14 has become an attractive research focus in recent years.

14-3-3 Protein: A Potential Drug Target

The 14-3-3 protein is a non-specified subtype of the GLUT14 protein. It is a 14 kDa protein that contains 135 amino acid residues. The 14-3-3 protein is expressed in various tissues, including muscle, liver, and brain. It is involved in the regulation of cell signaling pathways, including the TGF-β pathway.

The TGF-β pathway is a well-established signaling pathway that plays a crucial role in the development, maintenance, and regression of tissues. It is involved in various processes, including cell proliferation, differentiation, angiogenesis, and immune responses. Malfunctioning GLUT14 has has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Targeting GLUT14: A Promising Approach

Several strategies have been proposed to target GLUT14, including:

1. Chemical inhibitors: Several studies have shown that inhibitors of the 14-3-3 protein can inhibit its activity in cell signaling pathways, including the TGF-β pathway. These inhibitors include small molecules, peptides, and antibodies. One such study identified a small molecule inhibitor, N-[2-(3-isothiocyanatopyrrolidin-1-yl)--4-fluorobutane], which inhibited GLUT14-mediated TGF-β signaling in human cancer cells.

2. RNA interference: RNA interference (RNAi) is another approach that can be used to target GLUT14. RNAi involves the use of small interfering RNA (siRNA) to knockdown GLUT14 expression in cells. Several studies have shown that RNAi can be an effective method to target GLUT14 in various tissues, including muscle, liver, and brain.

3. Optimization of GLUT14: Some researchers have focused on optimizing GLUT14 to improve its activity or stability. One approach is to optimize the structure of GLUT14 to enhance its stability or to improve its interaction with other proteins. This can be achieved by modifying the amino acid residues or by using specific libraries of amino acids.

4. blocker of GLUT14-mediated signaling pathways: Some researchers have developed blockers to target GLUT14 and inhibit its activity in various signaling pathways. For example, a study identified a protein called P169, which is a GLUT14-interacting protein. P169 can inhibit GLUT14 -mediated TGF-β signaling and can be used as a potential drug target or biomarker.

Biomarker Potential

GLUT14 has also been suggested as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Several studies have shown that GLUT14 is involved in the development and progression of these diseases. For example, a study identified GLUT14 as highly expressed in human colorectal cancer and suggested that it may be a potential biomarker for this disease.

Another study showed that GLUT14 was involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The study identified GLUT14 as highly expressed in the brain and suggested that it may be a potential biomarker for these diseases.

Conclusion

In conclusion, GLUT14 is a non-specified subtype of the GLUT14 protein that is involved in the regulation of cell signaling pathways, including the TGF-β pathway. Malfunctioning GLUT14 has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders . As a result, targeting GLUT14 has become an attractive research focus in recent years. Several strategies have been proposed to target GLUT14, including chemical inhibitors, RNA interference, optimization of GLUT14, and blockers of GLUT14-mediated signaling pathways. Additionally, GLUT14 has has also been suggested as a potential biomarker for various diseases. Further research is needed to fully understand the role of GLUT14 in disease progression and to develop effective therapies targeting GLUT14.

Protein Name: 14-3-3 Protein (nonspecified Subtype)

The "14-3-3 Protein Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about 14-3-3 Protein comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets